CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model

Molecular Immunology

Volumn 48, Issue 1-3, 2010, Pages 219-230

  Ingersoll, Sarah A ^a,b   Martin, Carol B ^b   Barnum, Scott R ^d   Martin, Brian K ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b Iowa Cancer Research Foundation   (United States)

^c NEWLINK GENETICS   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Complement; Cuprizone; Neuroimmunology; Rodent; Transgenic Knockout mice

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CUPRIZONE; GLIAL FIBRILLARY ACIDIC PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CULTURE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CORPUS CALLOSUM; CYTOKINE PRODUCTION; DEMYELINATION; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMYELINIZATION; TRANSGENIC MOUSE;

ANIMALS; ASTROCYTES; BRAIN; COMPLEMENT C3A; COMPLEMENT C5A; CUPRIZONE; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; MONOAMINE OXIDASE INHIBITORS; NEUROIMMUNOMODULATION; OLIGODENDROGLIA; SIGNAL TRANSDUCTION;

MURINAE; MUS; MUS MUSCULUS; RODENTIA;

EID: 78649494476     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.08.007     Document Type: Article

References (64)

1. Albright A.V., Shieh J.T., Itoh T., Lee B., Pleasure D., O'Connor M.J., Doms R.W., Gonzalez-Scarano F. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J. Virol. 1999, 73:205-213.
2. Anderson R.D., Haskell R.E., Xia H., Roessler B.J., Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000, 7:1034-1038.
3. Armstrong R.C., Harvath L., Dubois-Dalcq M.E. Type 1 astrocytes and oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct molecules. J. Neurosci. Res. 1990, 27:400-407.
4. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
5. Bakker D.A., Ludwin S.K. Blood-brain barrier permeability during cuprizone-induced demyelination. Implications for the pathogenesis of immune-mediated demyelinating diseases. J. Neurol. Sci. 1987, 78:125-137.
6. Biancotti J.C., Kumar S., de Vellis J. Activation of inflammatory response by a combination of growth factors in cuprizone-induced demyelinated brain leads to myelin repair. Neurochem. Res. 2008, 33:2615-2628.
7. Boos L., Campbell I.L., Ames R., Wetsel R.A., Barnum S.R. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 2004, 173:4708-4714.
8. Boos L., Szalai A.J., Barnum S.R. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci. Lett. 2005, 387:68-71.
9. Briggs D.T., Martin C.B., Ingersoll S.A., Barnum S.R., Martin B.K. Astrocyte-specific expression of a soluble form of the murine complement control protein Crry confers demyelination protection in the cuprizone model. Glia 2007, 55:1405-1415.
10. Bsibsi M., Persoon-Deen C., Verwer R.W., Meeuwsen S., Ravid R., Van Noort J.M. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 2006, 53:688-695.
11. Cianflone K., Xia Z., Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 2003, 1609:127-143.
12. Davoust N., Jones J., Stahel P.F., Ames R.S., Barnum S.R. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 1999, 26:201-211.
13. Flynn G., Maru S., Loughlin J., Romero I.A., Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol. 2003, 136:84-93.
14. Fonseca M.I., Ager R.R., Chu S.H., Yazan O., Sanderson S.D., LaFerla F.M., Taylor S.M., Woodruff T.M., Tenner A.J. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 2009, 183:1375-1383.
15. Francis K., Lewis B.M., Akatsu H., Monk P.N., Cain S.A., Scanlon M.F., Morgan B.P., Ham J., Gasque P. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J. 2003, 17:2266-2268.
16. Gasque P., Singhrao S.K., Neal J.W., Gotze O., Morgan B.P. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am. J. Pathol. 1997, 150:31-41.
17. Gasque P., Singhrao S.K., Neal J.W., Wang P., Sayah S., Fontaine M., Morgan B.P. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J. Immunol. 1998, 160:3543-3554.
18. Gavrilyuk V., Kalinin S., Hilbush B.S., Middlecamp A., McGuire S., Pelligrino D., Weinberg G., Feinstein D.L. Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J. Neurochem. 2005, 92:1140-1149.
19. Gerard C., Gerard N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol. 1994, 12:775-808.
20. Groebe A., Clarner T., Baumgartner W., Dang J., Beyer C., Kipp M. Cuprizone treatment induces distinct demyelination, astrocytosis, and microglia cell invasion or proliferation in the mouse cerebellum. Cerebellum 2009, 8:163-174.
21. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 2005, 23:821-852.
22. Haas P.J., van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol. Res. 2007, 37:161-175.
23. Han Y., Wang J., Zhou Z., Ransohoff R.M. TGFbeta1 selectively up-regulates CCR1 expression in primary murine astrocytes. Glia 2000, 30:1-10.
24. Heese K., Hock C., Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J. Neurochem. 1998, 70:699-707.
25. Hiremath M.M., Saito Y., Knapp G.W., Ting J.P., Suzuki K., Matsushima G.K. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J. Neuroimmunol. 1998, 92:38-49.
26. Ingram G., Hakobyan S., Robertson N.P., Morgan B.P. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin. Exp. Immunol. 2009, 155:128-139.
27. Jacob A., Bao L., Brorson J., Quigg R.J., Alexander J.J. C3aR inhibition reduces neurodegeneration in experimental lupus. Lupus 2010, 19:73-82.
28. Jacob A., Hack B., Bai T., Brorson J.R., Quigg R.J., Alexander J.J. Inhibition of C5a receptor alleviates experimental CNS lupus. J. Neuroimmunol. 2010, 221:46-52.
29. Jauneau A.C., Ischenko A., Chan P., Fontaine M. Complement component anaphylatoxins upregulate chemokine expression by human astrocytes. FEBS Lett. 2003, 537:17-22.
30. Jauneau A.C., Ischenko A., Chatagner A., Benard M., Chan P., Schouft M.T., Patte C., Vaudry H., Fontaine M. Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J. Neuroinflammation 2006, 3:8.
31. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
32. Kondo A., Nakano T., Suzuki K. Blood-brain barrier permeability to horseradish peroxidase in twitcher and cuprizone-intoxicated mice. Brain Res. 1987, 425:186-190.
33. Ligon K.L., Alberta J.A., Kho A.T., Weiss J., Kwaan M.R., Nutt C.L., Louis D.N., Stiles C.D., Rowitch D.H. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 2004, 63:499-509.
34. Liu L., Belkadi A., Darnall L., Hu T., Drescher C., Cotleur A.C., Padovani-Claudio D., He T., Choi K., Lane T.E., Miller R.H., Ransohoff R.M. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
35. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
36. Marriott M.P., Emery B., Cate H.S., Binder M.D., Kemper D., Wu Q., Kolbe S., Gordon I.R., Wang H., Egan G., Murray S., Butzkueven H., Kilpatrick T.J. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia 2008, 56:686-698.
37. Mason J.L., Jones J.J., Taniike M., Morell P., Suzuki K., Matsushima G.K. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J. Neurosci. Res. 2000, 61:251-262.
38. Mason J.L., Suzuki K., Chaplin D.D., Matsushima G.K. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21:7046-7052.
39. Mason J.L., Xuan S., Dragatsis I., Efstratiadis A., Goldman J.E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 2003, 23:7710-7718.
40. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
41. McCarthy K.D., de Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 1980, 85:890-902.
42. McMahon E.J., Cook D.N., Suzuki K., Matsushima G.K. Absence of macrophage-inflammatory protein-1alpha delays central nervous system demyelination in the presence of an intact blood-brain barrier. J. Immunol. 2001, 167:2964-2971.
43. Morell P., Barrett C.V., Mason J.L., Toews A.D., Hostettler J.D., Knapp G.W., Matsushima G.K. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol. Cell. Neurosci. 1998, 12:220-227.
44. Mukherjee P., Thomas S., Pasinetti G.M. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J. Neuroinflammation 2008, 5:5.
45. Muller-Ladner U., Jones J.L., Wetsel R.A., Gay S., Raine C.S., Barnum S.R. Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J. Neurol. Sci. 1996, 144:135-141.
46. Nataf S., Levison S.W., Barnum S.R. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 2001, 894:321-326.
47. Neumann H., Kotter M.R., Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009, 132:288-295.
48. Nikcevich K.M., Piskurich J.F., Hellendall R.P., Wang Y., Ting J.P. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha. J. Neuroimmunol. 1999, 99:195-204.
49. Nolte C., Moller T., Walter T., Kettenmann H. Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996, 73:1091-1107.
50. Osaka H., McGinty A., Hoepken U.E., Lu B., Gerard C., Pasinetti G.M. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 1999, 88:1073-1082.
51. Osaka H., Mukherjee P., Aisen P.S., Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 1999, 73:303-311.
52. Qin H., Niyongere S.A., Lee S.J., Baker B.J., Benveniste E.N. Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J. Immunol. 2008, 181:3167-3176.
53. Rahpeymai Y., Hietala M.A., Wilhelmsson U., Fotheringham A., Davies I., Nilsson A.K., Zwirner J., Wetsel R.A., Gerard C., Pekny M., Pekna M. Complement: a novel factor in basal and ischemia-induced neurogenesis. EMBO J. 2006, 25:1364-1374.
54. Reiman R., Campos Torres A., Martin B.K., Ting J.P., Campbell I.L., Barnum S.R. Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neurosci. Lett. 2005, 390:134-138.
55. Reiman R., Gerard C., Campbell I.L., Barnum S.R. Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur. J. Immunol. 2002, 32:1157-1163.
56. Sayah S., Jauneau A.C., Patte C., Tonon M.C., Vaudry H., Fontaine M. Two different transduction pathways are activated by C3a and C5a anaphylatoxins on astrocytes. Brain Res. Mol. Brain Res. 2003, 112:53-60.
57. Shinjyo N., Stahlberg A., Dragunow M., Pekny M., Pekna M. Complement-derived anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor cells. Stem Cells 2009, 27:2824-2832.
58. Sidman R.L., Abervine J.B., Pierce E.T. Atlas of the Mouse Brain and Spinal Cord 1971, Harvard University Press, Cambridge, MA.
59. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
60. Stark J.L., Lyons J.A., Cross A.H. Interferon-gamma produced by encephalitogenic cells induces suppressors of cytokine signaling in primary murine astrocytes. J. Neuroimmunol. 2004, 151:195-200.
61. Torkildsen O., Brunborg L.A., Myhr K.M., Bo L. The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 2008, 188:72-76.
62. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
63. Woodruff T.M., Costantini K.J., Crane J.W., Atkin J.D., Monk P.N., Taylor S.M., Noakes P.G. The complement factor c5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 2008, 181:8727-8734.
64. Yao J., Harvath L., Gilbert D.L., Colton C.A. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 1990, 27:36-42.